Medical/Pharmaceuticals
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel
2021-09-15 15:27
2070
CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0
SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational ne...
2021-09-15 08:30
2268
Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®
SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve ("TAVR") system, following the first successful patient implant in Zhongshan Hospital of Fudan Univers...
2021-09-14 22:11
4390
PolyU develops groundbreaking and highly effective targeted osteoarthritis pain reliever
HONG KONG, Sept. 14, 2021 /PRNewswire/ -- Researchers at The Hong Kong Polytechnic University (PolyU) have developed a groundbreaking, imaging-guided nanoparticle photothermal treatment for osteoarthritis pain, utilising the concept of targeted cancer therapy but instead applied to the protein th...
2021-09-14 20:37
1693
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...
2021-09-14 18:57
1407
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...
2021-09-14 15:00
4978
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002
SHANGHAI, Sept. 14, 2021 /PRNewswire/ -- Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002). The clinical trial of JMB2002 was stated in January 2021. A single-center, rand...
2021-09-14 11:43
2395
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
2021-09-14 10:30
1641
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC
* Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstrate improvement in progression-free survival (PFS), after the primary efficacy endpoint was met at an interim PFS analysis last year * The updated data showed that the risk of disease progression or...
2021-09-14 08:30
2959
Global Investors Invest in Etana
JAKARTA, Indonesia, Sept. 14, 2021 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana)has secured a new round of investment led by Legend Capital along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM). This round of funds will b...
2021-09-14 08:00
6053
Immune Checkpoint Inhibitors Convey Survival Benefit in Elderly patients with Stage IV Non-Small Cell Lung Cancer
DENVER, Sept. 14, 2021 /PRNewswire/ -- Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients with non-s...
2021-09-13 23:00
1681
AnchorDx Develops New Liquid Biopsy Diagnostic Model for Early Detection of Breast Cancer
GUANGZHOU, China, Sept. 13, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned experts from a top-tier hospital inChina, jointly published an article entitled"Circulating cell-free DNA-based methylation patterns for b...
2021-09-13 21:00
2410
PharmAbcine to Participate in ACCESS CHINA Biotech Forum
DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...
2021-09-13 20:00
1094
I-Mab Added to FTSE ESG Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Env...
2021-09-13 20:00
4421
Future Forum Announced the Winners of 2021 Future Science Prize: Kwok-Yung Yuen, Joseph Sriyal Malik Peiris, Jie Zhang, Simon Sze
BEIJING, Sept. 13, 2021 /PRNewswire/ -- Future Science Prize announced the winners of 2021 inBeijing on September 12th. Prof. Kwok-Yung Yuen and Prof. Joseph Sriyal Malik Peiris won the Prize in life sciences for their discoveries of SARS-CoV-1 as the causative agent for the global SARS outbreak ...
2021-09-13 19:03
1587
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
5448
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
STATE COLLEGE, Pa., Sept. 13, 2021 /PRNewswire/ -- * FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell's first-in-human clinical studies * Drug substance manufacturing will be carried out in...
2021-09-13 18:00
1599
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
2021-09-13 17:00
1481
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
2021-09-13 17:00
3891
Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia (the "phase I study"). The clinical data abstract has...
2021-09-13 14:34
2672
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 255 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2937
